Loading stock data…
Kairos Pharma (KAPA)
$1.77-0.07 (-3.80%)
Market ClosedLast close Sep 8
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kairos Pharma, Ltd. in the Healthcare sector is trading at $1.77 with a market capitalization of $10M. Wall Street consensus targets $49.00 (2 analysts), implying a +2668.5% move over the next 12 months. The stock is currently near its 52-week low of $1.51, remaining 54.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +2668.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.69M↓ | -$1.42M↑ | -$1.44M↑ | -$1.46M↓ | -$1.27M |
| Net Income | -$1.65M↓ | -$1.36M↑ | -$1.40M↑ | -$1.42M↓ | -$1.26M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-109.90%
Volume
Today's trading volume
173,027
Recent News
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
Bayer’s share price has climbed sharply over the past year, yet the valuation checks still suggest the stock screens as cheap on several measures. This raises the question of how much of the recent optimism is already reflected in the price. Bayer has returned 70.4% over the past year, which puts recent gains front and center for anyone assessing what is already priced in. The new collaboration with Kairos Pharma around XOFIGO in metastatic prostate cancer can support sentiment around...
Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health
Bayer announced two new collaborations, one with Kairos Pharma on a prostate cancer therapy and another with Henry Ford Health on wider research across several diseases. The Kairos Pharma partnership focuses on combination treatments for metastatic prostate cancer. The alliance with Henry Ford Health covers cardiovascular, oncology, and women’s health research using advanced data and clinical technologies. Bayer, traded under XTRA:BAYN, is adding these research deals alongside a share price...
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy
Kairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
Kairos Pharma reports positive data from Phase II prostate cancer treatment trial
The trial consisted of subjects who had not responded to at least one form of hormone therapy previously.